F Fuzkk Atlas of India
#57FUZKK atlas leaders 1–100

Supriya Lifescience Ltd

Maharashtra · Maharashtra / Mumbai–Pune

API / CDMO / synthesis

Manufacturing profile

API / CDMO / synthesis

State / territory: Maharashtra

Pharmaceutical cluster: Maharashtra / Mumbai–Pune

Selection basis

The company is placed in positions 1–100 as a major Indian manufacturer, exporter, API/CDMO, generics, vaccine or biopharma participant.

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Licence status, GMP status and the actual site portfolio must be rechecked through CDSCO and the relevant State Drug Controller.

Representative manufacturing and QC chain

  1. 1Route development, raw materials and scale-up
  2. 2Synthesis, fermentation or process development
  3. 3Purification, crystallisation, filtration and drying
  4. 4Technology transfer, cleaning and change control
  5. 5HPLC/GC/KF/ICP/LC-MS and method-validation evidence

Relevant FUZKK packages

India: national essential medicines QC packageGlobal API & Biosimilars QC SuiteWorld API Extension QC SuiteFermentation & Antibiotic Intermediates QC SuiteLumex QC Suite

Product/API utilities

—

Lumex — instrumental QC

Method Validation Data Packager

LabEx — laboratory QC

Assay & Impurity HPLC Quality CheckerResidual Solvents GC Quality CheckerWater Content KF Quality CheckerElemental Impurities ICP Quality CheckerLC-MS Confirmation Quality Checker

Medical Devices — equipment and software lifecycle

Process Validation CheckerChange Control Impact CheckerSupplier Evaluation CheckerProduction Record Consistency CheckerCalibration Status CheckerRequirement Traceability CheckerData Integrity Security Checker

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Licence status, GMP status and the actual site portfolio must be rechecked through CDSCO and the relevant State Drug Controller.

Methodology